INV-71 / Innovimmune Biotherap - LARVOL DELTA

Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model (ESMO 2022) - "Conclusions The data presented highlight the potential therapeutic utility of pharmacological RORγ activation with synthetic oral INV-71 new chemical entities as a single-agent monotherapy. The synergistic antitumor effects of INV-71 as a combination treatment with anti-PD-1 hold promise as a novel immunotherapeutic treatment modality for cancer."

Checkpoint inhibition • IO biomarker • Preclinical • Breast Cancer • Oncology • Solid Tumor • IL17A